



## ASH 2022 abstracts: What's hot in MPN?

To help navigate the exciting content being presented at the 64th ASH Annual Meeting and Exposition, the MPN Hub Steering Committee have provided their recommendations of the top abstracts to look out for in MPN.

Brought to you by SES |  **Scientific Education Support**



Saturday, December 10, 2022

<b>235</b>	<a href="#"><u>Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)</u></a>	Jean-Jacques Kiladjian
<b>238</b>	<a href="#"><u>Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24</u></a>	John Mascarenhas
<b>327</b>	<a href="#"><u>Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis</u></a>	Bridget Marcellino
<b>330</b>	<a href="#"><u>Jak2<sup>V617F</sup> Reversible Activation Shows an Essential Requirement for Jak2<sup>V617F</sup> in Myeloproliferative Neoplasms (MPNs)</u></a>	Andrew Dunbar
<b>337</b>	<a href="#"><u>Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib</u></a>	Stephen Oh
<b>340</b>	<a href="#"><u>TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis</u></a>	Nico Gagelmann
<b>1728</b>	<a href="#"><u>Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm</u></a>	Angela Fleischman

Sunday, December 11, 2022

<b>6</b>	<a href="#"><u>Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)</u></a>	Edimara Reis
<b>627</b>	<a href="#"><u>Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor</u></a>	Aaron Gerds
<b>628</b>	<a href="#"><u>Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis</u></a>	Stephen Oh

Monday, December 12, 2022

<b>739</b>	<a href="#"><u>Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial</u></a>	Claire Harrison
<b>742</b>	<a href="#"><u>Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)</u></a>	Steffen Koschmieder
<b>743</b>	<a href="#"><u>Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial</u></a>	Trine Knudsen
<b>744</b>	<a href="#"><u>Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial</u></a>	Tiziano Barbui



Follow us on Twitter to keep up to date  
with the latest from the 64th ASH Annual  
Meeting and Exposition!

@MPN\_Hub  
#ASH22  
mpn-hub.com

 **Scientific Education Support**